



167

# HANUMANTRAO LAD & ASSOCIATES CHARTERED ACCOUNTANTS

## Independent Auditor's Report

To

The Members of

DR.SMITHS BIOTECH PRIVATE LIMITED.

### Report on the Financial Statements:

We have audited the accompanying financial statements of DR.SMITHS BIOTECH PRIVATE LIMITED which comprise the Profit and loss account, Balance Sheet & cash flow statement as at 31st March, 2021, for the year the ended and, and a summary of the significant accounting policies and other explanatory information.

### Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013("the Act") with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Accounting Standards specified under section 133 of the Act read with Rule 7 of the Companies (Accounts) Rule 2014. This responsibility includes maintenance of adequate accounting records in accordance with the provisions of the act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities ; selection and application of appropriate accounting policies , making judgments and estimates that are reasonable and prudent : and design, implementation and maintenance of adequate internal financial control that are operating effectively for enduring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

### Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and Rules made hereunder.

We conducted our audit in accordance with the Standards on Auditing specified under section 143 (10) of the Act. Those Standards require that we comply with the ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers the internal financial control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on financial statements.



## Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2021, & cash flows for the year ended on that date,

## Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, We give the annexure to our report statement on the matters specified in paragraphs 3 & 4 of the said order.

2. As required by Section 143 (3) of the Act, we report that:

(a) We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

(c) The Balance Sheet and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

(d) In our opinion, the Balance Sheet, and the Cash Flow Statement comply with the Accounting Standards specified under section 133 of the Act , read with Rule 7 of the Companies ( Accounts ) Rules , 2014.

(e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of section 164 (2) of the Act .

(f) With respect to the other matter to be included in the Auditors Report in accordance with Rule 11 of the Companies ( Audit & Auditors ) Rules 2014, In our opinion and the best of information and according to the explanation given to us:

i) There is no pending litigation on company affecting company's financial position

ii) The Company did not have any long term contracts including derivative contracts for which there were any material foreseeable losses:

iii) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Hanumantrao lad & Associates  
Chartered Accountants



CA.HANUMANTRAO LAD  
Proprietor  
Membership Number: 131606  
Firm Reg No: 129981W  
Place: Pune  
Date: 29<sup>th</sup> June 2021.



ANNEXURE TO THE INDEPENDENT AUDITORS REPORT (Referred to in paragraph (5) of our report on other legal and regulatory requirements of our report of even date)

On the basis of such checks as we considered appropriate and according to the information and explanation given to us during the course of our audit, we report that:

1. In respect of its fixed assets:
  - (a) The company has maintained proper records showing full particulars including quantitative details and situation of its fixed assets.
  - (b) As explained to us, fixed assets have been physically verified by the management at reasonable intervals; no material discrepancies were noticed on such verification.
  - (c) In our opinion and according to the information and explanations given to us, no fixed asset has been disposed during the year and therefore does not affect the going concern assumption.
2. In respect of its inventories:
  - (a) As explained to us, inventories have been physically verified during the year by the management at reasonable intervals.
  - (b) In our opinion and according to the information and explanations given to us, the procedures of physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the company and the nature of its business.
  - (c) In our opinion and on the basis of our examination of the records, the Company is generally maintaining proper records of its inventories. No material discrepancy was noticed on physical verification of stocks by the management as compared to book records.
3. In respect of the loans, secured or unsecured granted by the company to companies firms or other parties covered in the register maintained under section 189 of the Companies Act 2013:
  - (a) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not granted any loans, secured or unsecured, to companies, firms or other parties listed in the register maintained under Section 189 of the Companies Act, 2013. Consequently, the provisions of clauses iii (b), iii(c) and iii (d) of the order are not applicable to the Company.
  - (e) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has taken loans from companies, firms or other parties listed in the register maintained under Section 189 of the Companies Act, 2013.
4. In respect of its internal control:

In our opinion and according to the information and explanations given to us, there is generally an adequate internal control procedure commensurate with the size of the company and the nature of its business, for the purchase of inventories & fixed assets and payment for expenses & for sale of goods. During the course of our audit, no major instance of continuing failure to correct any weaknesses in the internal controls has been noticed.
5. In respect of its deposit from public:

The Company has not accepted any deposits from the public covered under section 73 to 76 of the Act and rules framed there under.
6. In respect of its maintenance of cost records:

The company is not covered by the companies cost record and Audit Rules 2014. Therefore the provisions of clause 6 of the order are not applicable to the company.
7. In respect of its statutory dues:
  - (a) According to the records of the company, undisputed statutory dues including Provident Fund, Investor Education and Protection Fund, Employees' State Insurance, Income-tax, Sales-tax, Wealth Tax, Service Tax, Custom Duty, Excise Duty, cess, goods and service tax to the extent applicable and any other statutory dues have generally been regularly deposited with the appropriate authorities. According to the information and explanations given to us there were no outstanding statutory dues as on 31st of March, 2021 for a period of more than six months from the date they became payable.



(b) According to the information and explanations given to us, there is no amounts payable in respect of income tax, wealth tax, service tax, sales tax, customs duty and excise duty which have not been deposited on account of any disputes.

8. In respect of its accumulated losses and cash losses:  
The Company does not have any accumulated loss and has not incurred cash loss during the financial year covered by our audit and in the immediately preceding financial year.
9. In respect of its dues to financial institution / banks/debentures:  
Based on our audit procedures and on the information and explanations given by the management, we are of the opinion that, the Company has not defaulted in repayment of dues to a financial institution, bank or debenture holders.
10. In respect of guarantee given for loans taken by others:  
According to the information and explanations given to us, the Company has not given any guarantees for loan taken by others from a bank or financial institution.
11. In respect of application of term loans :  
Based on the information and explanations given to us and on an overall examination of the Balance Sheet & profit and loss account of the Company as at 31st March, 2021, we report that no funds raised on short-term basis have been used for long-term investment by the Company.
12. In respect of fraud:  
Based on the audit procedures performed and the information and explanations given to us, we report that no fraud on or by the Company has been noticed or reported during the year, nor have we been informed of such case by the management.

For Hanumantrao Lad & Associates  
Chartered Accountants



CA.HANUMANTRAO LAD  
Proprietor  
Membership Number: 131606  
Firm No 129981W  
Place: Pune  
Date: 29<sup>th</sup> June 2021



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**STATEMENT OF STANDALONE BALANCESHEET AS AT MARCH 31ST, 2021**

Particulars		Note No.	As at 31 March,	As at 31 March,
			2021	2020
			Rs. In Lakh	Rs. In Lakh
<b>A</b>	<b>EQUITY AND LIABILITIES</b>			
1	<b>Shareholders' funds</b>			
	(a) Share capital	3	220.00	220.00
	(b) Reserves and surplus	4	(163.05)	(135.69)
	(c) Money received against share warrants	29.1		
			56.95	84.31
2	<b>Share application money pending allotment</b>	29.2		
3	<b>Non-current liabilities</b>			
	(a) Long-term borrowings	5	1,926.63	2,134.72
	(b) Deferred tax liabilities (net)		68.80	39.23
	(c) Other long-term liabilities	6	(44.57)	68.91
	(d) Long-term provisions	7	-	-
			1,950.86	2,242.86
4	<b>Current liabilities</b>			
	(a) Short-term borrowings	8	186.44	37.67
	(b) Trade payables	9	433.25	25.56
	(c) Other current liabilities	10	230.89	1.08
	(d) Short-term provisions	11	17.00	13.68
			867.58	77.99
	<b>TOTAL</b>		<b>2,875.39</b>	<b>2,405.16</b>
<b>B</b>	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	(a) Fixed assets			
	(i) Tangible assets	12.A	1,780.17	1,865.08
	(ii) Intangible assets	12.B	-	-
	(iii) Capital work-in-progress	12.C	22.52	22.41
	(iv) Intangible assets under development			
	(v) Fixed assets held for sale	29.9		
			1,802.69	1,887.49
	(b) Non-current investments	13		-
	(c) Deferred tax assets (net)			
	(d) Long-term loans and advances	14	9.76	148.81
	(e) Other non-current assets	15	100.00	100.00
			109.76	248.81
2	<b>Current assets</b>			
	(a) Current investments	16	-	-
	(b) Inventories	17	501.58	-
	(c) Trade receivables	18	182.94	3.95
	(d) Cash and cash equivalents	19	11.52	43.50
	(e) Short-term loans and advances	20	266.90	221.40
	(f) Other current assets	21	-	-
			962.94	268.85
	<b>TOTAL</b>		<b>2,875.39</b>	<b>2,405.16</b>
	See accompanying notes forming part of the financial statements			

**NOTES TO ACCOUNTS**

Schedules referred to above and notes attached there to form an integral part of Balance Sheet  
 This is the Balance Sheet referred to in our Report of even date.

FOR HANUMANTRAO LAD & ASSOCIATES  
 CHARTERED ACCOUNTANTS

(CA. HANUMANTRAO LAD)  
 Proprietor  
 Membership No. : 131606  
 Firm Reg. No.: 129981W  
 UDIN NO : 21131606AAAFF1054



DR.SMITHS BIOTECH PVT LTD

(DIRECTOR) (DIRECTOR)  
 Suraj Zanwar Riyaz Khan  
 DIN-01304850 DIN- 07578366  
 PLACE: PUNE PLACE: PUNE  
 Date: 29/06/2021 Date: 29/06/2021



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**STATEMENT OF STANDALONE PROFIT AND LOSS FOR THE YEAR ENDED ON MARCH 31ST, 2021**

Particulars	Note No.	For the year ended March 31, 2021	For the year ended March 31, 2020
		Rs. (in Lakhs)	Rs. (in Lakhs)
<b>A CONTINUING OPERATIONS</b>			
1 Revenue from operations (gross)	22	398.60	5.18
2 Other income	23	7.74	7.36
<b>3 Total revenue (1+2)</b>		<b>406.34</b>	<b>12.54</b>
<b>4 Expenses</b>			
(a) Cost of materials consumed	24.a	197.42	-
(b) Purchases of stock-in-trade	24.b	49.33	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	24.c	-227.23	-
(d) Other Operating Expenses	25	73.10	19.39
(d) Employee benefits expense	26	23.42	8.56
(e) Finance costs	27	151.32	131.09
(f) Depreciation and amortisation expense	12.a & 12.b	100.13	199.42
(g) Other expenses	28	35.71	13.98
<b>Total expenses</b>		<b>403.19</b>	<b>372.44</b>
<b>5 Profit / (Loss) before exceptional and extraordinary items and tax (3 - 4)</b>		<b>3.15</b>	<b>-359.90</b>
6 Exceptional items	29.a		
<b>7 Profit / (Loss) before extraordinary items and tax (5 ± 6)</b>		<b>3.15</b>	<b>-359.90</b>
8 Extraordinary items	29.b	0.95	
<b>9 Profit / (Loss) before tax (7 ± 8)</b>		<b>2.21</b>	<b>-359.90</b>
<b>10 Tax expense:</b>			
(a) Current tax expense for current year			
(b) (Less). MAT credit (where applicable)			
(c) Current tax expense relating to prior years			
(d) Net current tax expense			
(e) Deferred tax		29.57	11.62
		29.57	11.62
<b>11 Profit / (Loss) from continuing operations (9 ± 10)</b>		<b>-27.36</b>	<b>-371.52</b>
<b>B DISCONTINUING OPERATIONS</b>			
12.i Profit / (Loss) from discontinuing operations (before tax)			
12.ii Gain / (Loss) on disposal of assets / settlement of liabilities attributable to the discontinuing operations			
12.iii Add / (Less): Tax expense of discontinuing operations			
(a) on ordinary activities attributable to the discontinuing operations			
(b) on gain / (loss) on disposal of assets / settlement of liabilities			
<b>13 Profit / (Loss) from discontinuing operations (12.i ± 12.ii ± 12.iii)</b>			
<b>14 Profit / (Loss) for the year (11 ± 13)</b>		<b>-27.36</b>	<b>-371.52</b>
<b>15.i Earnings per share (22,00,000 Shares of Rs. 10/- each):</b>			
(a) Basic			
(i) Continuing operations		-1.24	-16.89
(ii) Total operations			
(b) Diluted			
(i) Continuing operations		-1.24	-16.89
(ii) Total operations			
<b>15.ii Earnings per share (22,00,000 Shares of Rs. 10/- each):</b>			
(a) Basic			
(i) Continuing operations		-1.24	-16.89
(ii) Total operations			
(b) Diluted			
(i) Continuing operations		-1.24	-16.89
(ii) Total operations			



FOR HANUMANTRAO LAD & ASSOCIATES  
CHARTERED ACCOUNTANTS

DR.SMITHS BIOTECH PVT LTD

*Hanumantrao Lad*



(CA. HANUMANTRAO LAD)

Proprietor

Membership No. : 131606

Firm Reg. No.: 129981W

UDIN NO : 21131606AAAAEF7054

*Suraj Zanwar*

(DIRECTOR)

Suraj Zanwar

DIN-01304850

PLACE: PUNE

Date : 29/06/21

*Riyaz Khan*

(DIRECTOR)

Riyaz Khan

DIN- 07578366

PLACE: PUNE

Date : 29/06/2021



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**STATEMENT OF STANDALONE CASHFLOW AS AT 31.03.2021**

Particulars	As at 31 March, 2021	As at 31 March, 2020
	Rs. In Lakh	Rs. In Lakh
<b>Cash Flow from operating activities</b>		
Net Profit after tax	-27.36	-371.52
Adjustment for:		
- Other Comprehensive Income		
- Depreciation and amortization expense	100.13	199.42
- (Profit) / Loss on Sale/Disposal of assets		
- Interest Expenses	151.28	131.05
- Interest & Dividend received	-7.74	-7.36
- Deferred Tax Liability		
<b>Operating profit before working capital changes</b>	<b>216.31</b>	<b>-48.41</b>
(Increase) / Decrease in Other Non Current asset		
(Increase) / Decrease in Inventories	-501.58	
(Increase) / Decrease in Trade receivables	-178.99	-0.51
(Increase) / Decrease in Other Current Assets	-45.50	3.55
Increase / (Decrease) in Provisions	3.32	11.09
Increase / (Decrease) in Trade Payables	407.69	216.35
Increase / (Decrease) in Other Financial Liabilities/Short Term Borrowing	148.77	-108.73
Increase / (Decrease) in Defferd tax liabilities	29.57	11.62
Increase / (Decrease) in Other Current Liabilities	229.81	-0.63
<b>Cash generated from operations</b>	<b>309.40</b>	<b>84.32</b>
Taxes paid		
<b>Net cash from operating activities</b>	<b>309.40</b>	<b>84.32</b>
<b>Cash flow from Investing activities</b>		
Purchase of fixed assets	-15.22	-71.08
Proceeds from sale of fixed assets		
(Increase) / Decrease in Capital Work in Progress	-0.11	-21.37
Interest & Dividend received	7.74	7.36
Proceeds / (Repayment) of Other Financial Assets	139.05	-142.62
<b>Net Cash flow from investing activities</b>	<b>131.47</b>	<b>-227.72</b>
<b>Cash flow from financing activities</b>		
Proceeds from issuance of Share Capital including share premium		
Proceeds from long term borrowings	-208.09	651.26
Proceeds / (Repayment) from / of short term borrowings (Above)		
Proceeds / (Repayment) for Other Financial Assets	-113.48	-342.46
Interest paid	-151.28	-131.05
<b>Net Cash flow from Financing Activities</b>	<b>-472.85</b>	<b>177.76</b>
<b>Increase / (Decrease) in cash and cash equivalents</b>	<b>-31.98</b>	<b>34.36</b>
Cash and cash equivalents at beginning of the year	43.50	9.14
<b>Cash and cash equivalents at end of the year</b>	<b>11.52</b>	<b>43.50</b>

**Notes :**

- i) Cash Flow Statement has been prepared under the indirect method as set out in the Accounting Standard (AS) 3 "Cash Flow Statements" as specified in the Companies (Accounting Standards) Rules, 2006.
- ii) Details of Cash and cash equivalents are given in note No 2.06
- iii) Direct Tax paid is treated as arising from operating activities and are not bifurcated between investment and financing activities.
- iv) All figures in brackets indicate outflow.

**FOR HANUMANTRAO LAD & ASSOCIATES**  
**CHARTERED ACCOUNTANTS**

**DR.SMITHS BIOTECH PVT LTD**





*Palae*



(CA. HANUMANTRAO LAD)  
Proprietor  
Membership No. : 131606  
Firm Reg. No.: 129981W  
UDIN NO : 21131606AAAAEFT054

*[Signature]*

(DIRECTOR)  
Suraj Zanwar  
DIN-01304850  
PLACE: PUNE

*[Signature]*

(DIRECTOR)  
Riyaz Khan  
DIN- 07578366  
PLACE: PUNE  
Date : 29/6/2021



DR. SMITHS BIOTECH PRIVATE LIMITED  
SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,  
PUNE MH 411048 IN  
CIN: U24246PN2015PTC154818

NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021

**Note 1: Corporate Information**

DR. SMITHS BIOTECH PRIVATE LIMITED ("The Company") is a Private Limited Company as was incorporated and domiciled in India having its registered office at SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR, PUNE MH 411048 IN The Company is engaged in the Manufacturing and marketing of pharmaceutical products.

The Company has its manufacturing plant situated at B-5, Khasara No. 9 & 10, Dev Bhoomi Industrial Estate, Gram: Bantakhedi, Tal: Roorkee, Dist: Haridwar (Uttarakhand) India

**Note 2: Significant Accounting Policies**

**2.01 Basis of accounting and Preparation of Accounting Statements**

**A) Compliance with Accounting Standards**

The Financial Statements of the company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP) The company has prepared these financial statements to comply in all material respects with the accounting standards notified under section 133 of the Companies Act 2013, read together with paragraph 7 of the Companies (Accounts) Rules 2014. The financial statements have been prepared on an accrual basis and under the historical cost convention. The financials are prepared according to Indian Accounting Standards (AS)

**B) Current and Non-current classification**

The assets and liabilities reported in the balance sheet are classified on a "current/noncurrent basis", with separate reporting of assets held for sale and corresponding liabilities. Current assets, which include cash and cash equivalents are assets that are intended to be realized, sold or consumed during the normal operating cycle of the Company. Based on the nature of products and the time between the acquisition of assets for processing and their realisation in cash and cash equivalents, the company has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets and liabilities.

**2.02 Use of estimates**

The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of revenues and expenses during the year and balances of assets, liabilities and the disclosure of contingent liabilities on the date of the financial statements. Actual results could differ from those estimates. Any revision to accounting estimates is recognized prospectively in current and future periods.

**2.03 Inventories**

Inventories of Raw Material, Packing Material and Stock-in-Trade are valued at the lower of cost and the net realisable value after providing for obsolescence and other losses, where considered necessary. Cost includes all charges in bringing the goods to the point of sale, including octroi and other levies, transit insurance and receiving charges excluding GST. The costs are valued at Weighted Average cost Formula.

Work in Progress are valued at the cost of Conversion of inventories, includes cost directly related to the units of production, such as direct labour. There is stage wise systematic allocation of fixed and variable production overheads that are incurred.

Finished Goods are valued at net realizable value or cost whichever is lower. Valuation of Cost of finished good includes all the conversion costs directly attributable to product and other Administrative overheads.

The inventories have been certified by the management for both physical verification and valuation.

The inventories are kept at the below mentioned location by the company for the Closing stock as on March 31st, 2021

**Plant/Factory situated at**

**Address:** B-5, Khasara No. 9 & 10, Dev Bhoomi Industrial Estate, Gram: Bantakhedi, Tal: Roorkee, Dist: Haridwar (Uttarakhand) India

**2.04 Cash and Cash Equivalent**

Cash and cash equivalents comprises cash on hand and at banks, short-term deposits (with an original maturity of three months or less from the date of acquisition), and which are subject to insignificant risk of changes in value.

For the purpose of statement of cash flows, cash and cash equivalents consist of cash and short term deposits, as defined above, net of outstanding bank overdrafts, if any, as they are considered an integral part of the company's cash management.

**2.05 Cash flow statement**

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments. The cash flows from operating, investing and financing activities of the Company are segregated based on the available information.

**2.06 Depreciation**

Depreciation has been provided on the straight-line method as per the prescribed in Schedule II of the Companies Act, 2013 and assets are amortised as per their useful life as under

Land	0 Years
Building	30 Years
Computers	3 Years
Furnitures	10 Years
Office Equipments	5 Years
Plant & Machinery	10 Years
Vehicles	8 Year

Depreciation on additions/ disposals of the fixed assets during the year is provided on pro-rata basis according to the period during which assets were put to use.

During the year the part of the company was not operational due to COVID-19 Pandemic. Hence the management has decided to claim 50% depreciation only

Intangible assets are amortised over their estimated useful life is considered 5 years as per the management decision

The company does not possess any block of intangible assets.



## 2.07 Revenue recognition

- a) Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue are exclusive of Goods and Service Tax and net of discounts, applicable taxes and returns. The company recognises revenue when the amount of revenue can be reliably measured, when it is probable that future economic benefits will flow to the entity and when specific criteria have been met for each of the company's activities, as described below.
- b) Provision for sales returns are estimated on the basis of historical experience, market conditions and specific contractual terms and provided for in the year of sale as reduction from revenue. The methodology and assumptions used to estimate returns are monitored and adjusted regularly in line with contractual and legal obligations, trade practices, historical trends, past experience and projected market conditions.
- c) Other income:
- Dividend income is recognized when the right to receive dividend is established.
  - Interest income is recognized using the time-proportion method, based on rates implicit in the transaction.
  - Other income is recognised when no significant uncertainty as to its determination or realisation exists.

## 2.08 Fixed Assets

### Tangible fixed assets

Property, Plant and Equipment are stated at cost of acquisition/construction net of recoverable taxes less accumulated depreciation / amortization, government grants and impairment loss, if any. All costs attributable to acquisition of Property, Plant and Equipment till assets are put to use, are capitalized. Subsequent expenditure on Property, Plant and Equipment after its purchase / completion is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

### Capital work-in-progress:

Projects under which assets are not ready for their intended use and other capital work-in-progress are carried at cost, comprising direct cost, related incidental expenses and attributable interest.

### Intangible Assets

Intangible assets are carried at cost less accumulated amortisation and impairment losses, if any. The cost of an intangible asset comprises its purchase price, including any import duties and other taxes (other than those subsequently recoverable from the taxing authorities), and any directly attributable expenditure on making the asset ready for its intended use and net of any trade discounts and rebates. Subsequent expenditure on an intangible asset after its purchase / completion is recognised as an expense when incurred unless it is probable that such expenditure will enable the asset to generate future economic benefits in excess of its originally assessed standards of performance and such expenditure can be measured and attributed to the asset reliably, in which case such expenditure is added to the cost of the asset.

## 2.09 Foreign currency transactions and translations

### Initial recognition

Transactions in foreign currencies entered into by the Company and its integral foreign operations are accounted at the exchange rates prevailing on the date of the transaction or at rates that closely approximate the rate at the date of the transaction.

### Measurement of foreign currency monetary items at the Balance Sheet date

Foreign currency monetary items (other than derivative contracts) of the Company and its net investment in non-integral foreign operations outstanding at the Balance Sheet date are restated at the year-end rates.

In the case of integral operations, assets and liabilities (other than non-monetary items), are translated at the exchange rate prevailing on the Balance Sheet date. Non-monetary items are carried at historical cost. Revenue and expenses are translated at the average exchange rates prevailing during the year. Exchange differences arising out of these translations are charged to the Statement of Profit and Loss.

### Treatment of exchange differences

Exchange differences arising on settlement / restatement of short-term foreign currency monetary assets and liabilities of the Company and its integral foreign operations are recognised as income or expense in the Statement of Profit and Loss.

## 2.10 Government grants, subsidies and export incentives

Government grants and subsidies are recognised when there is reasonable assurance that the Company will comply with the conditions attached to them and the grants / subsidy will be received. Government grants whose primary condition is that the Company should purchase, construct or otherwise acquire capital assets are presented by deducting them from the carrying value of the assets. The grant is recognised as income over the life of a depreciable asset by way of a reduced depreciation charge.

Export benefits are accounted for in the year of exports based on eligibility and when there is no uncertainty in receiving the same.

## 2.11 Investments

Long-term investments (excluding investment properties), are carried individually at cost less provision for diminution, other than temporary, in the value of such investments. Current investments are carried individually, at the lower of cost and fair value. Cost of investments include acquisition charges such as brokerage, fees and duties.

Investment properties are carried individually at cost less accumulated depreciation and impairment, if any. Investment properties are capitalised and depreciated (where applicable) in accordance with the policy stated for Tangible Fixed Assets. Impairment of investment property is determined in accordance with the policy stated for Impairment of Assets.

## 2.12 Employee benefits

### i) Short Term Employee Benefits

Short term employee benefits are expensed as & when the related service is provided. A liability is recognised for the amount expected to be paid if the company has existing legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.

### ii) Long-Term Employee Benefits

The liability for the earned leave is not expected to be settled wholly within twelve months after the end of the period in which the employees render the related service. They are therefore measured as the present value of expected future payments to be made in respect of services provided by employees upto the end of reporting period with actuarial valuations being carried out at each balance sheet date. The benefits are discounted using market yields at the end of the reporting period that have terms approximating to the terms of the related obligations.

### iii) Post Employment Benefits

#### a) Defined Contribution Plan

Payments to defined contribution retirement benefit plans are recognised as expenses when the employees have rendered the service entitling themselves to the contribution.

The Company recognises the such contributions as and expenses when incurred.

## 2.13 Employee share based payments

Company has not announced any employee stock option scheme during the year.



#### 2.14 Borrowing costs

Borrowing costs specifically relating to the acquisition, construction or production of qualifying assets that necessarily takes a substantial period of time to get ready for its intended use are capitalized ( net of income on temporarily deployment of funds) as part of the cost of such assets. Borrowing costs consist of interest and other costs that the company incurs in connection with the borrowing of funds.

For general borrowing used for the purpose of obtaining a qualifying asset, the amount of borrowing costs eligible for the capitalization is determined by applying a capitalization rate to the expenditure on that assets. The capitalization rate is the weighted average of the borrowing costs applicable to the borrowings of the company that are outstanding during the period, other than borrowings made specifically for the purpose of obtaining a qualifying assets.

All other borrowing costs are recognized in profit and loss in the period in which they are incurred.

The amount of borrowing costs capitalized during a period does not exceed the amount of borrowing costs incurred during that period.

#### 2.15 Earnings Per Share

Basic earnings per share is computed by dividing the profit or loss attributable to equity shareholders of the Company by the number of equity shares outstanding during the year. Diluted earnings per share is the same as basic earnings per share as the company does not have any dilutive potential equity shares outstanding. The number of equity shares are adjusted for share splits and bonus shares, as appropriate.

#### 2.16 Taxes on Income

Current tax is the tax payable on the taxable profit for the year, using tax rates enacted or substantively enacted by the end of reporting period by the governing taxation laws, and any adjustment to tax payable in respect of previous periods. Income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred taxes arising from deductible and taxable temporary differences between the tax base of assets and liabilities and their carrying amount in the financial statements are recognized using substantively enacted tax rates and laws expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled. Deferred tax asset are recognized only to the extent that it is probable that future taxable profit will be available against which the deductible temporary differences can be utilized. The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax assets to be utilized.

#### 2.17 Leases:

Lease arrangements where the risks and rewards incidental to ownership of an asset substantially vest with the lessor are recognised as operating leases. Operating lease payments are recognized as an expense on a straight line basis over the lease term unless the payments are structured to increase in line with the expected general inflation so as to compensate for the lessor's expected inflationary cost increases.

#### 2.18 Provisions, Contingent Liabilities and Contingent Assets

##### Provisions:

Provisions are recognized only when there is a present obligation as a result of past events and it is probable that an outflow of resources will be required to settle the obligation in respect of which a reliable estimate can be made.

##### Contingent liability:

- Possible obligations which will be confirmed only by future events not wholly within the control of the company. or
- Present obligations arising from past events where it is not probable that an outflow of resources will be required to settle the obligation or a reliable estimate of the amount of the obligation cannot be made.

##### Contingent Assets

A contingent asset is a possible asset that arises from past events and whose existence will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the Company. Contingent assets are not recognised and disclosed only when an inflow of economic benefits is probable.



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

**Note 3: Share Capital**

Particulars	As at March 31, 2021		As at March 31, 2020	
	Number of shares	Amount (Rs. In Laks)	Number of shares	Amount (Rs. In Laks)
(a) Authorised Equity shares of Rs. 10.00 each with voting rights	2,500,000.00	250.00	2,500,000.00	250.00
(b) Issued Equity shares of Rs. 10.00 each with voting rights	2,200,000.00	220.00	2,200,000.00	220.00
(c) Subscribed and fully paid up Equity shares of Rs. 10.00 each with voting rights	2,200,000.00	220.00	2,200,000.00	220.00
<b>Total</b>	<b>2,200,000.00</b>	<b>220.00</b>	<b>2,200,000.00</b>	<b>220.00</b>

**Reconciliation of the number of shares and amount outstanding at the beginning and at the end of the reporting period:**

Particulars	As at March 31, 2021		As at March 31, 2020	
	Number of shares	Amount (Rs. In Laks)	Number of shares	Amount (Rs. In Laks)
As at the beginning of the year	2,200,000.00	220.00	2,200,000.00	220.00
As at the end of the year	2,200,000.00	220.00	2,200,000.00	220.00

**Shareholders holding more than 5% shares in the Company**

Name of the Shareholder	As at March 31, 2021		As at March 31, 2020	
	Number of shares	% of Shareholding	Number of shares	% of Shareholding
Suraj Zanwar (Nominee Share Holder On behalf of Cian Healthcare Limited)	1	0.00%	1	0.00%
Cian Healthcare Limited	2,199,999	100.00%	2,199,999	100.00%
<b>Total</b>	<b>2,200,000</b>	<b>100.00%</b>	<b>2,200,000</b>	<b>100.00%</b>



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

Note 4: Reserves and Surplus	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at March 31, 2021	As at March 31, 2020
<b>Reserves and surplus</b>		
<u>(a) Securities premium account</u>		
Opening balance	294.50	294.50
Add : Premium on shares issued during the year		
Less : Utilised during the year for:		
Issuing bonus shares		
Writing off preliminary expenses		
Writing off shares / debentures issue expenses		
Premium on redemption of redeemable preference shares / debentures		
Buy back of shares		
Closing balance		
<u>(b) General reserve</u>		
Balance brought forward from last year	-430.19	-58.67
Add: Profit/ (Loss) for the year	-27.36	-371.52
Closing balance	-457.55	-430.19
<u>(c) Depreciation Revaluation Reserve</u>		
<b>Total</b>	-163.05	-135.69



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

<b>Note 5: Long Term Borrowings</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at March 31, 2021	As at March 31, 2020
<b>Long Term Loans from Banks-Secured</b>		
Term Loan SIDBI-D0000WO9	36.33	41.33
Term Loan SIDBI-D0000WOB	12.37	16.46
Term Loan SIDBI-D0000X4V	1,023.78	1,146.79
Term Loan SIDBI FITL-D0002TBE	58.53	72.04
TERM LOAN-SIDBI (Immovable property or any interest therein; Book debts; Movable property (not being pledge); Two Fixed deposit receipts of INR 5000000/- each)	-	-
<b>Total-Long Term Loans from Banks-Secured</b>	<b>1,131.01</b>	<b>1,276.62</b>
<b>Loans &amp; Advances from Related Parties</b>		
Dhiraj Zanwar	66.57	66.57
Kavita Zanwar	122.40	122.65
Suraj Zanwar	606.65	668.87
<b>Total- Loans &amp; Advances from Related Parties</b>	<b>795.62</b>	<b>858.10</b>
<b>Total Long Term Borrowings</b>	<b>1,926.63</b>	<b>2,134.72</b>
<b>Note 6: Other Long Term Liabilities</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at March 31, 2021	As at March 31, 2020
(i) Payables on purchase of fixed assets	-44.57	68.91
(ii) Contractually reimbursable expenses		
(iii) Interest accrued but not due on borrowings		
(iv) Interest accrued on trade payables		
(v) Interest accrued on others		
(vi) Trade / security deposits received		
(vii) Advances from customers		
(viii) Income received in advance (Unearned revenue)		
(ix) Others		
<b>Total</b>	<b>-44.57</b>	<b>68.91</b>
<b>Note 7: Long Term Provision</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at March 31, 2021	As at March 31, 2020
<b>(a) Provision for employee benefits:</b>		
(i) Provision for compensated absences		
(ii) Provision for gratuity (net)		
(iii) Provision for post-employment medical benefits		
(iv) Provision for other defined benefit plans (net) (give details)		
(v) Provision for other employee benefits		
<b>(b) Provision for Other:</b>		
<b>Total</b>	<b>-</b>	



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

<b>Note 8: Short Term Borrowings</b>		(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>		<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
<b>A</b>	<b>Current maturities of Long Term Borrowings</b>		
	<u>(i) From banks</u>		
	Secured Loans	178.08	37.6675
	Accrued Interest On Term Loan Payable	8.36	
<b>B</b>	<b>Loans Replayable on Demand</b>		
	<u>(i) From banks</u>		
	Secured Loans		
<b>Total</b>		<b>186.44</b>	<b>37.67</b>
<b>Note 9: Trade Payable</b>		(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>		<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
Due to MSME creditors			
	Due To Small & Micro	58.85	32.05
	Due to Medium	0.50	
Trade payables to related parties			
Others Trade payables		373.90	-6.49
<b>Total Trade Payable</b>		<b>433.25</b>	<b>25.56</b>
<b>Note 10: Other Current Liabilities</b>		(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>		<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
(a) Other payables			
	(i) Statutory remittances (Contributions to PF and ESIC, TDS.)	0.74	1.08
	(ii) Payables on purchase of fixed assets		
	(iii) Salary and Remuneration Payable	4.45	-
	(iv) Interest accrued on trade payables		
	(v) Interest accrued on others		
	(vi) Trade / security deposits received		
	(vii) Advances from customers	225.70	
	(vii) Other Payable- Employee Expenses	-	-
<b>Total</b>		<b>230.89</b>	<b>1.08</b>
<b>Note 11: Short-term provisions</b>		(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>		<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
(a) Provision for employee benefits: @			
	(i) Provision for bonus		
	(ii) Provision for compensated absences		
	(iii) Provision for gratuity (net) (Refer Note 30.4.b)		
	(iv) Provision for post-employment medical benefits (Refer Note 30.4.b)		
	(v) Provision for other defined benefit plans (net) (give details) (Refer Note 30.4.b)		
	(vi) Provision for other employee benefits (give details)		
(b) Provision - Others:			
	(i) Provision for Tax		
	(ii) Provision - others	17.00	13.68
<b>Total</b>		<b>17.00</b>	<b>13.68</b>





Note 9: Trade Payable		(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars		As at March 31, 2021	As at March 31, 2020
SUNDRY CREDITORS FOR -RAW MATERIAL-RK	04-01B-00002	253.28	-
SUNDRY CREDITORS FOR-PACKING MATERIAL-RK	04-01B-00003	122.00	-
SUNDRY CREDITORS FOR -EXPENSES-RK	04-01B-00004	34.70	25.56
SUNDRY CREDITORS FOR -TRADING GOODS-RK	04-01B-00005	23.39	-
SUNDRY CREDITORS FOR -EXPENSES-HO	04-01A-00004	-0.13	-
SUSPENSE CREDITORS	13-02A000001	-	-
SUNDRY CREDITORS FOR -TRADING GOODS-HO	04-01A-00005	-	-
<b>Total</b>		<b>433.25</b>	<b>25.56</b>
Note 10: Other Current Liabilities		(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars		As at March 31, 2021	As at March 31, 2020
(i) Statutory remittances (Contributions to PF and ESIC, TDS.)			
TDS PAYABLE - CONTRACT - ROORKEE	04-07A-00007	0.54	0.59
TDS PAYABLE - PROF FEE ROORKEE	04-07A-00008	0.15	0.45
TCS PAYABLE	04-07A-00010	0.04	0.04
TCS Payable on Sales of Goods	04-07A-00014	-	-
TDS PAYABLE	04-07A-00011	-0.00	-0.00
		<b>0.74</b>	<b>1.08</b>
(iii) Salary and Remuneration Payable			
SALARY PAYABLE - HOLD	04-10A-00005	0.00	-
SALARY PAYABLE - DR. SMITHS	04-10A-00019	3.86	-
SALARY & REM. OT PAYABLE- DR. SMITHS(PRO)	04-10B-00004	0.59	-
		<b>4.45</b>	-
(vii) Other Payable- Employee Expenses			
EXPENSES - ANKUSH BHANDARI	04-09A-00007	-	-
EXPENSES - ANIL BALE	04-09A-00046	-	-
EXPENSES - YASHI GUPTA	04-09A-00111	-	-
		-	-
Note 14: Long Term Loans and Advances		(Rs. In Lakhs)	
Particulars		As at March 31, 2020	
DEPOSIT - ELECTRICITY ROORKEE	06-09A-00004	9.01	4.94
DEPOSIT - UEPPCB - POLLUTION	06-09A-00034	0.75	0.75
		<b>9.76</b>	<b>5.69</b>
Note 15: Other Non-Current Assets		(Rs. In Lakhs)	
FIXED DEPOSIT NO.0769106000034450	15-01A-00005	50.00	50.00
FIXED DEPOSIT NO. 0769106000034478	15-01A-00006	50.00	50.00
		<b>100.00</b>	<b>100.00</b>
Note 19: Cash and Cash Equivalent		(Rs. In Lakhs)	
Particulars		As at March 31, 2020	
(a) Cash in Hand			
CASH-OFFICE	06-02A-00001	0.08	0.08
CASH - ROORKEE	06-02B-00001	0.54	0.03
		<b>0.63</b>	<b>0.11</b>
(c) Balances with banks			
(i) In current accounts			
IDBI BANK - A/C 769102000003971	06-03A-00018	2.13	0.15
ICICI BANK C/A. NO. 325705500146 -DSBPVL	06-03A-00025	0.51	-
ICICI A/C - 325705500146	06-03A-00032	-	35.23
IDBI BANK CC - 0769658400000019	06-03A-00031	0.10	0.10
ICICI BANK MOD A/C	06-03B-00003	-0.20	-
		<b>2.54</b>	<b>35.48</b>
(iii) In deposit accounts			
FIXED DEPOSITS - IDBI BANK	15-01A-00008	-	-
FIXED DEPOSIT NO. 0007107000146784	15-01A-00003	6.19	5.86
FIXED DEPOSIT NO.0007107000147149	15-01A-00004	2.16	2.05
		<b>8.36</b>	<b>7.91</b>



Note 20: Short Term Loans and Advances		(Rs. In Lakhs)	
Particulars		As at March 31, 2020	
(f) Balances with government authorities			
(iv) GST credit available			
IGST Payable-UTTI	04-14D-00001	-10.33	-
CGST Payable-UTT	04-14D-00002	0.01	-
SGST Payable-UTT	04-14D-00003	0.01	-
IGST Reverse Charge Payable-UTT	04-14D-00004	-0.01	-
CGST Reverse Charge Payable-UTT	04-14D-00005	-0.07	-
SGST Reverse Charge Payable-UTT	04-14D-00006	-0.07	-
IGST Credit Receivable (Inputs)-UTT	06-14D-00001	165.71	178.21
CGST Credit Receivable (Inputs)-UTT	06-14D-00002	54.93	21.24
SGST Credit Receivable (Inputs)-UTT	06-14D-00003	54.92	21.24
CGST Reverse Charge (Input)-UTT	06-14D-00017	-	-
SGST Reverse Charge (Input)-UTT	06-14D-00018	-	-
		<b>265.10</b>	<b>220.68</b>
(v) TDS Receivable			
TDS RECIEVABLE FY 2019-20	06-06A-00020	0.72	0.72
TDS RECIEVABLE FY 2020-21	06-06A-00022	0.58	-
		<b>1.30</b>	<b>0.72</b>



DR. SMITHS BIOTECH PRIVATE LIMITED  
 SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,  
 PUNE Pune MH 411048 IN  
 CIN: U24246PN2015PTC154818

NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021

Note:12A: Fixed Asset-Tangible Assets

Sr. No.	Particulars	Gross Block as on 31st March, 2020	Additions	(Disposal)/Subsidy	Gross Block as on 31st March, 2021	Depreciation			W.D.V. as on 31st March, 2021	W.D.V. as on 31st March, 2020
						As on 31st March, 2020	For the period	On disposals		
1	Land	105.08	-	-	105.08	-	-	-	105.08	105.08
2	Building	437.99	-	-	437.99	7.30	-	23.68	414.31	421.61
3	Computer	8.03	-	-	8.03	1.34	-	4.30	3.73	5.06
4	Plant & Machinery	1,286.80	9.84	-	1,296.64	78.93	-	254.45	1,042.19	1,111.28
5	Furniture & Fixtures	248.75	5.38	-	254.13	12.56	-	39.27	214.86	222.04
	<b>Total</b>	<b>2,086.65</b>	<b>15.22</b>	<b>-</b>	<b>2,101.86</b>	<b>100.13</b>	<b>-</b>	<b>321.69</b>	<b>1,780.17</b>	<b>1,865.08</b>

Note:12B: Fixed Asset-Intangible Assets

Sr. No.	Particulars	Gross Block as on 31st March, 2020	Additions	(Disposal)/Subsidy	Gross Block as on 31st March, 2021	Depreciation			W.D.V. as on 31st March, 2021	W.D.V. as on 31st March, 2020
						As on 31st March, 2020	For the period	On disposals		
1	Intangible Assets	-	-	-	-	-	-	-	-	-
	<b>Total</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>

Note:12C: Fixed Asset-Capital Work in Progress

Sr. No.	Particulars	Gross Block as on 31st March, 2020	Additions	Transferred to Fixed Assets	Closing as on 31st March, 2021	Closing as on 31st March, 2020
	<b>Total</b>	<b>22.41</b>	<b>0.11</b>	<b>0</b>	<b>22.52</b>	<b>22.41</b>

Note:12D: Change of depreciation due to correction in useful life for 18-19

Plant & Machinery closing balance is increased by Rs. 0.32 Lakhs and depreciation value is reduced by the same amount on account of excess depreciation charged during 2018-2019

Due to covid-19 outbreak plant of our company was closed during Apr-20 to Sep-20, all the records and GSTR shows that there are no activities on the plant as well as office. For better presentation of the records depreciation on all assets has been charged to 50%. MRL will be provided in this regards



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**

**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

<b>Note 13: Non-Current Investment</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
<u>Investments</u>		
<b>Total</b>	-	-


<b>Note 14: Long Term Loans and Advances</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
<u>(a) Capital advances *</u>		
Secured, considered good	0	143.12
Unsecured, considered good		
Doubtful	-	143.12
Less: Provision for doubtful advances	-	143.12
<u>(b) Security deposits</u>		
Secured, considered good	9.76	5.69
Unsecured, considered good		
Doubtful	9.76	5.69
Less: Provision for doubtful deposits	9.76	5.69
<u>(c) Loans and advances to related parties (Refer Note 30.7)</u>		
Secured, considered good		-
Unsecured, considered good		-
Doubtful		-
Less: Provision for doubtful loans and advances	-	-
<u>(d) Balances with government authorities</u>		
Unsecured, considered good		
(i) CENVAT credit receivable		
(ii) VAT credit receivable		
(iii) Service Tax credit receivable		
	-	-



DR. SMITHS BIOTECH PRIVATE LIMITED  
SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,  
PUNE Pune MH 411048 IN  
CIN: U24246PN2015PTC154818

NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST,  
2021

<b>Total</b>	<b>9.76</b>	<b>148.81</b>



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**

**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST,**  
**2021**

<b>Note 15: Other Non-Current Assets</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
(a) Long-term trade receivables # (including trade receivables on deferred credit terms)		
Secured, considered good		
Unsecured, considered good		
Doubtful		
Less: Provision for doubtful trade receivables		
(b) Unamortised expenses		
(i) Ancillary borrowing costs		
(ii) Share issue expenses (where applicable)		
(iii) Discount on shares (where applicable)		
(iv) Other: Long Term Deposits with Banks	100.00	100.00
(Fixed deposit receipts of INR 5000000/- each are mortgage against the Term Loan)		
	100.00	100.00
<b>Total</b>	<b>100.00</b>	<b>100.00</b>

<b>Note 16: Current Investments</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
<b>Total</b>		-



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

<b>Note 17: Inventories</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
(a) Raw Material	196.51	
(b) Work-in-progress	50.31	
(c) Finished goods (Manufactured)	176.92	
(d) Stock-in-trade (acquired for trading)	-	
(e) Packing Material	77.83	
<b>Total</b>	<b>501.58</b>	<b>-</b>

<b>Note 18: Trade Receivable</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
Trade receivables outstanding for a period exceeding six months from the date Secured, considered good		
Unsecured, considered good		
Doubtful		
Less: Provision for doubtful trade receivables	-	-
Other Trade receivables Secured, considered good	177.61	3.95
Unsecured, considered good	-	
Doubtful	5.32	
Less: Provision for doubtful trade receivables	182.94	3.95
<b>Total</b>	<b>182.94</b>	<b>3.95</b>

<b>Note 19: Cash and Cash Equivalent</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
(a) Cash in Hand	0.63	0.11
(b) Cheques, drafts on hand		



(c) Balances with banks		
(i) In current accounts	2.54	35.48
(ii) In EEFC accounts		
(iii) In deposit accounts	8.36	7.91
<b>Total</b>	<b>11.52</b>	<b>43.50</b>





**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST,**  
**2021**

<b>Note 20: Short Term Loans and Advances</b>			(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at March 31, 2021	As at March 31, 2020		
(a) Loans and advances to related parties				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Less: Provision for doubtful loans and advances	0	0		
(b) Security deposits				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Less: Provision for doubtful deposits	0	0		
(c) Loans and advances to employees				
Secured, considered good	0.50	-		
Unsecured, considered good				
Doubtful	0.50	-		
Less: Provision for doubtful loans and advances	0.50	-		
(d) Loans and advances to Others				
Secured, considered good				
Unsecured, considered good				
Doubtful				
Less: Provision for doubtful deposits	-	-		
(e) Prepaid expenses - Unsecured, considered good				
(f) Balances with government authorities				
Unsecured, considered good				
(i) CENVAT credit receivable				
(ii) VAT & CST credit receivable				
(iii) Service Tax credit receivable				
(iv) GST credit available	265.10	220.68		
(v) TDS Receivable	1.30	0.72		
	266.40	221.40		
<b>Total</b>	<b>266.90</b>	<b>221.40</b>		
<b>Note 21: Other Current Assets</b>			(Rs. In Lakhs)	(Rs. In Lakhs)
Particulars	As at March 31, 2021	As at March 31, 2020		
<b>Total</b>	<b>0</b>	<b>0</b>		



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

<b>Note 22: Revenue from Operations</b>			(Rs. In Lakhs)	(Rs. In Lakhs)
	Particulars	As at March 31, 2021	As at March 31, 2020	
Sales-Domestic		416.38		5.18
Export Sales		-		
Less: Goods Return		17.78		
<b>Total Revenue from Operations</b>		<b>398.60</b>		<b>5.18</b>
<b>Note 23: Other Income</b>			(Rs. In Lakhs)	(Rs. In Lakhs)
	Particulars	As at March 31, 2021	As at March 31, 2020	
Interest on Bank Fixed Deposits		7.74		7.33
Interest on Income Tax Refund		-		0.03
<b>Total Other Income</b>		<b>7.74</b>		<b>7.36</b>
<b>Note 24.a : Cost of Material Consumed</b>			(Rs. In Lakhs)	(Rs. In Lakhs)
	Particulars	As at March 31, 2021	As at March 31, 2020	
Opening Stock during the Year				-
Raw Material				
Packing Material				
Add: Purchases during the period				
Raw Material		356.20		
Packing Material		115.56		
Custom Charges				
		<b>471.76</b>		-
Less: Closing Stock during the Year				
Raw Material		196.51		
Packing Material		77.83		
		<b>274.34</b>		-
<b>Total Cost of Material consumed</b>		<b>197.42</b>		-
<b>Note 24.b : Purchases of Trading Goods</b>			(Rs. In Lakhs)	(Rs. In Lakhs)
	Particulars	As at March 31, 2021	As at March 31, 2020	
Purchases- Finished Goods		-		
Purchases-TR- Expenses		49.33		
Sample Purchases		-		
		-		
<b>Total</b>		<b>49.33</b>		-
<b>Note 24.c Changes in inventories of finished goods, work-in-progress and stock-in-trade</b>			(Rs. In Lakhs)	(Rs. In Lakhs)
	Particulars	As at March 31, 2021	As at March 31, 2020	
Inventories at the end of the year:				
Finished goods		176.92		
Work-in-progress		50.31		
Stock-in-trade				
		<b>227.23</b>		-
Inventories at the beginning of the year:				
Finished goods				
Work-in-progress				



DR. SMITHS BIOTECH PRIVATE LIMITED  
SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,  
PUNE Pune MH 411048 IN  
CIN: U24246PN2015PTC154818

NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021

Stock-in-trade		
Net Increase/Decrease in the Year	-227.23	-



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

<b>Note 25: Other Operating Expenses</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
Product Development Charges		
Foil / Cylinder Charges		
Electricity, Power and Fuel	41.28	18.40
Transportation Charges	0.39	0.04
Freight Inward charges	0.82	
Labour Charges	30.61	
Other Charges/Direct Expenses	-	0.94
<b>Total</b>	<b>73.10</b>	<b>19.39</b>
<b>Note 26: Employee Benefit Expenses</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
Salaries and Wages	20.38	8.04
Directors Remuneration	-	
Contribution / provisions to and for provident, Gratuity and other funds	-	
Salary & Wages Overtime	1.93	
Canteen	0.79	
Staff welfare expenses	0.32	0.52
<b>Total</b>	<b>23.42</b>	<b>8.56</b>
<b>Note 27: Finance Costs</b>	(Rs. In Lakhs)	(Rs. In Lakhs)
<b>Particulars</b>	<b>As at March 31, 2021</b>	<b>As at March 31, 2020</b>
Interest Expenses		
On Term Loan	151.28	131.05
On Cash Credit	-	
Other Financial Expenses	0.04	0.04
(Includes Bank Charges, Loan Processing Fess and other Finance Charges)	-	
<b>Total</b>	<b>151.32</b>	<b>131.09</b>



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

**Note 28: Other Admin Expenses**

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at March 31, 2021	As at March 31, 2020
Water Charges	0.14	
Repairs And Maintenance	6.81	1.55
Other Charge	2.22	1.31
Round-Off	-0.00	-0.00
Roc Expenses	0.02	0.07
Professional Fee	0.96	0.66
Documentation Charges	0.02	
Security Charges	7.68	7.38
Electricity, Water & Fuel	-	
Factory Expenses	0.10	
Analytical & Testing Charges - Roorkee	2.32	
Processing Charges-Purchase	0.01	
Diesel For Dg	2.33	
Consumable Stores & Accessories	2.17	
Internet Expenses	0.16	
Visitor Related Expenses	0.06	
Expenses - Office	0.01	
Freight Outward Charges	0.03	
Computer Maintainance	0.02	
GST Late Filing Fee	0.00	
Amc Charges	0.05	
Building Repairs & Maintenance	2.04	
Product Registration	0.19	
Export Product Registration Charges	0.51	
Cleaning Charges	0.11	
Rent Charges - Datt Infrastructure	0.28	-0.28
Round Off	-0.00	-
Write off	-0.20	
Interest And Late Fees On Taxes	0.19	0.44
Insurance Expenses	2.71	1.34
Printing And Stationery	0.36	0.31
Travelling & Conveyance	1.40	0.35
Audit Fees	3.00	0.75
Telephone And Internet Expenses		0.10
	-	
	-	



Total	35.71	13.98
-------	-------	-------



**DR. SMITHS BIOTECH PRIVATE LIMITED**  
**SN-593, OPP MALBAR HILL, SINDH HIND SOCY, LULLA NGR,**  
**PUNE Pune MH 411048 IN**  
**CIN: U24246PN2015PTC154818**

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDING MARCH 31ST, 2021**

**Note 29.1 Monies received against share warrants- Not Applicable**

**Note 29.2 Share application money pending allotment:** There is no such pending amounts. All the shares are fully paid and allotted

**Note 29. a) Exceptional Items**

There are no Exceptional Items to be disclosed

**Note 29. b) Extraordinary Items**

Particulars	As at March 31, 2021	As at March 31, 2020
Prior period Income		
Prior period Expenses	0.95	
	<b>0.95</b>	-

**Note 29. c) Disclosures required under Section 22 of the Micro, Small and Medium Enterprises Development Act, 2006**

Particulars	(Rs. In Lakhs)	(Rs. In Lakhs)
	As at March 31, 2021	As at March 31, 2020
(i) Principal amount remaining unpaid to any supplier as at the end of the accounting year		
a) Micro	23.71	18.32
b) Small	35.14	13.73
c) Medium	0.50	-

Dues to Micro and Small Enterprises have been determined to the extent such parties have been identified on the basis of information collected by the Management. This has been relied upon by the auditors.

The company has duly filed MSME-I for the period April-20-Sep-20 and Oct-20 to March-21 as per the prescribed format and disclosed all the required details.

Above outstanding includes the amount payable to Capital Creditors also which is included in Note: 14: Long Term Loans and Advances (Capital Advances) and others included in Trade payables which includes payable for RM, FG & other Expenses.

**Note 29. d) Foreign Currency Exposure**

Company is not involved in any Foreign Currency Transaction

**Note 29 e) Payment to auditors**

Payment to Statutory Auditors includes

Particulars	2020-2021	2019-2020
Payment for Statutory Audit	3.00	0.75
Payment for Tax Audit		
Payment for Company Law Matters		
Payment for Other Services		
<b>Total</b>	<b>3.00</b>	<b>0.75</b>

**29 f) Disclosure for borrowings**

The company has availed secured long term loan from the lender. Details for the same are as below.

Loan	Lender Name	Amount of Loan Sanctioned	Principal Outstanding as on 31.03.2021	Rate of Interest	Mortgage/Securities given against Loan
TERM LOAN-SIDBI-D0000WO9	Small Industries Development Bank of India	49.32	42.33	10.60%	Land, Building and Plant and Plant and Machinery and Other Fixed
TERM LOAN-SIDBI-D0000WOB	Small Industries Development Bank of India	20.00	16.46	10.30%	Assets situated at B-5, Khasara No; 9 & 10 Dabhbumi industrial Estate

